Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 1 Urine flow rates for the groups randomized to lixivaptan or placebo. The top panel presents data after single-blind placebo administration (baseline). The bottom panel depicts results after administration of double-blind study medication, consisting of either placebo or one of six doses of lixivaptan as indicated. At 1 h, urine flow was significantly increased at the higher doses of lixivaptan. At 2 h, urine flow was significantly increased at all doses >10 mg. See text for specific p values.
|
